A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies

Inclusion Criteria

• Recurrent, locally advanced or metastatic solid tumor cancer excluding the following: MSI-low colorectal cancer, glioblastoma multiforme, prostate cancer, pancreatic cancer, mucosal and ocular melanoma.
• Receipt of all standard therapies for the tumor type
• Measurable (target) disease by iRECIST
• If of childbearing potential (male or female), agrees to practice an effective form of contraception during study treatment and for at least 3 months following last treatment
• Willingness to undergo a pre-treatment and on-treatment biopsy, if required Key

Exclusion Criteria

• History of severe hypersensitivity reactions to other monoclonal antibodies.
• Previous treatment with any anti-CD27 antibody.
• Inadequate washout period from prior therapy as defined in the Protocol.
• Patients who have received more than 0 or 1 prior PD-1/PD-L1 inhibitor depending on their tumor type
• Major surgery within 4 weeks prior to study treatment.
• Use of immunosuppressive medications within 4 weeks or systemic corticosteroids within 2 weeks prior to study treatment.
• Other prior malignancy, except for adequately treated basal or squamous cell skin cancer or in situ cancers. For all other cancers, the patient must be disease-free for at least 3 years to be allowed to enroll.
• Thrombotic events within the last 6 months prior to study treatment
• Active, untreated central nervous system metastases.
• Active autoimmune disease or documented history of autoimmune disease.
• History of (non-infectious) pneumonitis or has current pneumonitis.
• Active diverticulitis
• Known infection of HIV, Hepatitis B, or Hepatitis C. There are additional criteria your study doctor will review with you to confirm your eligibility for the study.